{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:27:54Z","timestamp":1793392074849,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Virttu\/Sorrento and the ECMC Network"},{"name":"Weston Park Cancer Charity, Sheffield, UK"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.lungcan.2020.10.007","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T12:06:24Z","timestamp":1603195584000},"page":"145-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Oncolytic herpesvirus therapy for mesothelioma \u2013 A phase I\/IIa trial of intrapleural administration of HSV1716"],"prefix":"10.1016","volume":"150","author":[{"given":"Sarah J.","family":"Danson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munitta","family":"Muthana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulazeez","family":"Salawu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hodgkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Learmonth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penella J.","family":"Woll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.10.007_bib0005","series-title":"The Global Cancer observatory. Mesothelioma Report","year":"2020"},{"key":"10.1016\/j.lungcan.2020.10.007_bib0010","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1378\/chest.127.3.909","article-title":"Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion","volume":"127","author":"Dresler","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2020.10.007_bib0020","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1001\/jama.2012.5535","article-title":"Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME-2 randomized control trial","volume":"307","author":"Davies","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2020.10.007_bib0025","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2017.17426","article-title":"Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial","volume":"318","author":"Thomas","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2020.10.007_bib0030","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1089\/hum.1998.9.7-1083","article-title":"Adenovirus-mediated herpes simplex virus thymidine kinase\/ganciclovir gene therapy in patients with localised malignancy: results of a phase 1 clinical trial in malignant mesothelioma","volume":"9","author":"Sterman","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0035","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1089\/hum.1998.9.14-2121","article-title":"Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase 1 clinical trial for localised mesothelioma","volume":"9","author":"Molnar-Kimber","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0040","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1158\/1078-0432.CCR-05-0405","article-title":"Long-term follow up of patients with malignant pleural mesothelioma receiving high dose adenovirus herpes simplex thymidine kinase\/ganciclovir suicide gene therapy","volume":"11","author":"Sterman","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.lungcan.2020.10.007_bib0045","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A phase I clinical trial of single-dose intrapleural IFN-B gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses","volume":"13","author":"Sterman","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"Pt 7","key":"10.1016\/j.lungcan.2020.10.007_bib0050","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1099\/0022-1317-69-7-1531","article-title":"The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1","volume":"69","author":"McGeoch","year":"1988","journal-title":"J. Gen. Virol."},{"issue":"Pt 11","key":"10.1016\/j.lungcan.2020.10.007_bib0055","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1099\/0022-1317-69-11-2831","article-title":"The DNA sequences of the long repeat region and adjoining parts of the long unique region in the genome of herpes simplex virus type 1","volume":"69","author":"Perry","year":"1988","journal-title":"J. Gen. Virol."},{"issue":"13","key":"10.1016\/j.lungcan.2020.10.007_bib0060","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with Talimogene Laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0065","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1099\/0022-1317-75-12-3679","article-title":"ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro","volume":"75","author":"Brown","year":"1994","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0070","first-page":"466","article-title":"Use of a \"replication-restricted\" herpes virus to treat experimental human malignant mesothelioma","volume":"57","author":"Kucharczuk","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0075","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jgm.877","article-title":"Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses","volume":"8","author":"Adusumilli","year":"2006","journal-title":"J. Gene Med."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0080","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/cbt.5.1.2237","article-title":"Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma","volume":"5","author":"Adusumilli","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0085","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.gt.3301184","article-title":"Toxicity evaluation of replication-competent herpes simplex virus (ICP34.5) in patients with recurrent malignant glioma","volume":"7","author":"Rampling","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0090","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.gt.3301664","article-title":"The potential for efficacy of the modified (ICP34.5) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study","volume":"9","author":"Papanastassiou","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0095","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/sj.gt.3302289","article-title":"HSV1716 injection into the brain adjacent to tumour following surgical resection of high grade glioma: safety data and long-term survival","volume":"22","author":"Harrow","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0100","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/hed.20840","article-title":"Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma","volume":"30","author":"Mace","year":"2008","journal-title":"Head Neck"},{"key":"10.1016\/j.lungcan.2020.10.007_bib0105","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(00)04048-4","article-title":"Intralesional injection of herpes simplex virus 1716 in metastatic melanoma","volume":"357","author":"MacKie","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2020.10.007_bib0110","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1158\/1078-0432.CCR-16-2900","article-title":"Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients","volume":"23","author":"Streby","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0115","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.ymthe.2019.08.020","article-title":"First-in-human intravenous Seprehvir in young cancer patients: a phase 1 clinical trial","volume":"27","author":"Streby","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0125","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jmv.1890320202","article-title":"Establishment of PCR for the early diagnosis of herpes simplex encephalitis","volume":"32","author":"Puchhammer-St\u00f6ckl","year":"1990","journal-title":"J. Med. Virol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.10.007_bib0130","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ymthe.2017.03.026","article-title":"Oncolytic virotherapy: a contest between apples and oranges","volume":"25","author":"Russell","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0135","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N","article-title":"Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma","volume":"74","author":"Boutin","year":"1994","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2020.10.007_bib0140","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1378\/chest.121.6.1921","article-title":"Intrapleural infusion of activated macrophages and \u03b3interferon in malignant pleural mesothelioma","volume":"121","author":"Monnet","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2020.10.007_bib0145","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3","article-title":"Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"83","author":"Astoul","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2020.10.007_bib0150","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ejcts.2006.11.046","article-title":"A phase II study of intrapleural immuno-chemotherapy, pleurectomy\/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma","volume":"31","author":"Lucchi","year":"2007","journal-title":"Eur. J. Cardiothor. Surg."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0155","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1183\/09031936.94.07101889","article-title":"Implantable access system for prolonged intrapleural immunotherapy","volume":"7","author":"Driesen","year":"1994","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2020.10.007_bib0160","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1378\/chest.121.3.821","article-title":"Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion","volume":"121","author":"Shoji","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2020.10.007_bib0165","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/s41598-017-02503-8","article-title":"Cooperation of oncolytic herpes virotherapy and PD-1 blockade in murine rhabdomyosarcoma models","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:47:28Z","timestamp":1759236448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220306590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":33,"alternative-id":["S0169500220306590"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.10.007","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic herpesvirus therapy for mesothelioma \u2013 A phase I\/IIa trial of intrapleural administration of HSV1716","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}